Novavax, Inc. (NVAX) vs Vir Biotechnology, Inc. (VIR)
Novavax, Inc. and Vir Biotechnology, Inc. are both Biotechnology companies. Novavax, Inc. and Vir Biotechnology, Inc. are of similar size ($1.8B and $1.8B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,495.9% against −61.6%. Novavax, Inc. has the higher net margin (−59.9% vs −83.0%) and the higher return on invested capital (0.00% vs −39.1%). Across the 17 metrics below, Novavax, Inc. leads on 13 and Vir Biotechnology, Inc. on 4.
Valuation
Profitability
| Metric | NVAX | VIR | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.60% | 100.00% | 65.16% |
| Operating margin | (56.58%) | (92.40%) | 0.00% |
| Net margin | (59.87%) | (83.00%) | 0.00% |
| Free cash flow margin | (10.20%) | (67.17%) | 0.00% |
| Return on equity | 323.66% | (26.08%) | (57.72%) |
| Return on assets | (21.62%) | (20.91%) | (49.22%) |
| Return on invested capital | 0.00% | (39.10%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack